This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Ampio's Failed Drug Partner Talks Forces Spin-Out Plan

Ampio Pharmaceuticals' (AMPE - Get Report) plan to cast off its premature ejaculation and erectile dysfunction drugs into a separate publicly traded company is a nice bit of spin necessitated by the failure to find a partner for the drugs or start late-stage clinical trials by year's end, as previously promised. 

The new standalone company, Viryx Pharmaceuticals, will be tasked with developing Zertane and Zertane ED, Ampio announced Friday. Zertane is a mint-flavored tablet formulation of the old and generic painkiller tramadol. An initial public offering of Viryx shares will be attempted, with Ampio retaining 50-80% ownership stake.

Ampio CEO Michael Macaluso:

The spin off and subsequent funding, if completed, would give both Ampio and Vyrix greater flexibility to focus on and pursue their respective development strategies while potentially providing shareholders with greater value over the longer term.

Must Read: Gilead Hep C Drug Launch Threatened by Price Concerns

Yet for most of the last two years, pursuing the approval of Zertane and finding a partner were Ampio's stated goals. Phase III studies required for U.S. approval were supposed to start by the end of 2012. Ampio missed that deadline.  Management's promises to find a partner for Zertane this year have also gone unfulfilled.

Friday's announcement was short on details about how, exactly, Ampio was going to accomplish the Viryx public offering. The new company has a CEO, Jarret Disbrow, the former CEO of Arbor Pharmaceuticals, but little else. A registration statement for the proposed Viryxa IPO has not been filed with the SEC.

Ampio said the process could take up to a year to complete and the company doesn't intend to provide investors with regular updates. Of course, this means the start of the required Zertane clinical trials is being delayed even further. 

Why investors would be interested in owning newly minted Viryx shares also isn't clear. Zertane is not unique.  It's a new use for the old and generic (i.e. cheap and widely available) painkiller tramadol, formulated into a mint-flavored tablet that dissolves quickly in the mouth. Ampio claims the safest and most efficacious dosages of Zertane for premature ejaculation are 62 mg and 89 mg. Rather random-sounding dosing, except when you understand that standard tramadol can be easily prescribed at a 50 mg dose. Few doctors are going to prescribe Zertane at a higher cost when regular tramadol is already available and much cheaper.

Investors have had a healthy appetite for biotech and drug IPOs this year, although not much lately. Several recent IPOs have been cancelled due to lack of investor interest. 

Last month, Oculus Innovative Sciences (OCLS - Get Report) failed to spin off its prescription-grade diluted bleach product into a new public company called Ruthigen. Ampio's Viryx sounds a lot like Ruthigen.

Ampio shares closed Friday at $6.74.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AMPE $2.37 0.00%
OCLS $1.52 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs